Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.53 Million SEK | 15.9% |
| 2022 | 6.5 Million SEK | -70.14% |
| 2021 | 21.78 Million SEK | 217.46% |
| 2020 | 6.86 Million SEK | 309.56% |
| 2019 | 1.67 Million SEK | -81.31% |
| 2018 | 8.96 Million SEK | 1944.11% |
| 2017 | 438.4 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 18.39 Million SEK | 146.21% |
| 2024 Q2 | 7.47 Million SEK | -9.21% |
| 2024 Q1 | 8.22 Million SEK | 9.15% |
| 2023 Q2 | 7.31 Million SEK | -1.11% |
| 2023 Q4 | 7.53 Million SEK | 59.3% |
| 2023 FY | 7.53 Million SEK | 15.9% |
| 2023 Q3 | 4.73 Million SEK | -35.28% |
| 2023 Q1 | 7.39 Million SEK | 13.68% |
| 2022 FY | 6.5 Million SEK | -70.14% |
| 2022 Q4 | 6.5 Million SEK | -32.07% |
| 2022 Q3 | 9.57 Million SEK | -4.56% |
| 2022 Q2 | 10.03 Million SEK | 13.41% |
| 2022 Q1 | 8.84 Million SEK | -59.39% |
| 2021 Q1 | 8.91 Million SEK | 29.98% |
| 2021 FY | 21.78 Million SEK | 217.46% |
| 2021 Q4 | 21.78 Million SEK | 302.23% |
| 2021 Q3 | 5.41 Million SEK | -29.78% |
| 2021 Q2 | 7.71 Million SEK | -13.52% |
| 2020 Q3 | 2.69 Million SEK | 0.0% |
| 2020 FY | 6.86 Million SEK | 309.56% |
| 2020 Q4 | 6.86 Million SEK | 154.96% |
| 2019 FY | 1.67 Million SEK | -81.31% |
| 2018 FY | 8.96 Million SEK | 1944.11% |
| 2017 FY | 438.4 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 92.928% |
| Ziccum AB (publ) | 6.38 Million SEK | -18.003% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -219.542% |
| BioArctic AB (publ) | 139.5 Million SEK | 94.597% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 78.216% |
| Mendus AB (publ) | 51.22 Million SEK | 85.285% |
| Genovis AB (publ.) | 98.04 Million SEK | 92.312% |
| Intervacc AB (publ) | 21.68 Million SEK | 65.231% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 71.776% |
| Active Biotech AB (publ) | 13.4 Million SEK | 43.746% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 93.92% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 53.23% |
| Aptahem AB (publ) | 8.99 Million SEK | 16.224% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 81.551% |
| Kancera AB (publ) | 17.97 Million SEK | 58.071% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 83.677% |
| Fluicell AB (publ) | 8.91 Million SEK | 15.446% |
| Saniona AB (publ) | 86.08 Million SEK | 91.243% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -46.142% |
| Biovica International AB (publ) | 34.76 Million SEK | 78.319% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 35.396% |
| AcouSort AB (publ) | 10.37 Million SEK | 27.366% |
| Xintela AB (publ) | 14.01 Million SEK | 46.215% |
| Abliva AB (publ) | 16.78 Million SEK | 55.08% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 96.487% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 34.843% |
| OncoZenge AB (publ) | 1.69 Million SEK | -343.673% |
| Amniotics AB (publ) | 10.54 Million SEK | 28.529% |
| 2cureX AB (publ) | 2.93 Million SEK | -156.831% |
| CombiGene AB (publ) | 4.15 Million SEK | -81.376% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -70.312% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.519% |
| Camurus AB (publ) | 414.81 Million SEK | 98.183% |
| Corline Biomedical AB | 6.78 Million SEK | -11.033% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 87.715% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 60.666% |
| I-Tech AB | 16.2 Million SEK | 53.483% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.364% |
| Cyxone AB (publ) | 4.69 Million SEK | -60.588% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 43.442% |
| Biosergen AB | 5.08 Million SEK | -48.24% |
| Cantargia AB (publ) | 54.97 Million SEK | 86.287% |
| NextCell Pharma AB | 13.68 Million SEK | 44.934% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 89.509% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 45.264% |
| Nanologica AB (publ) | 79.32 Million SEK | 90.498% |
| SynAct Pharma AB | 51.83 Million SEK | 85.457% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 5.17% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -45.103% |
| LIDDS AB (publ) | 3.75 Million SEK | -100.692% |
| BioInvent International AB (publ) | 90.45 Million SEK | 91.666% |
| Alzinova AB (publ) | 9.33 Million SEK | 19.216% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 95.849% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -320.178% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 59.241% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -96.404% |
| Simris Alg AB (publ) | 148.93 Million SEK | 94.939% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 89.401% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.437% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 40.851% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -3.829% |